AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

AstraZeneca (LSE: AZN) has reported positive findings from its Phase III MATTERHORN trial, spotlighting the potential of its ...

A simple blood test could help breast cancer patients get the proper treatment earlier, potentially halving their risk of ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

AstraZeneca (LSE:AZN) recently announced promising clinical trial results for ENHERTU, which may reflect its ongoing ...

Patients with newly diagnosed gastric or gastroesophageal junction (GEJ) cancer who received the PD-L1 inhibitor durvalumab ...

AstraZeneca (LSE:AZN) received a positive recommendation from the European Medicines Agency for its cancer therapy Imfinzi, ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance ...